Cephalon To File Treanda For Two Oncology Indications This Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Company is on track to file chronic lymphocytic leukemia indication in Q3, followed by non-Hodgkin’s lymphoma in Q4.
You may also be interested in...
Cephalon Files Treanda For Chronic Lymphocytic Leukemia
Submission represents a milestone for Cephalon’s oncology program, firm says.
Cephalon Files Treanda For Chronic Lymphocytic Leukemia
Submission represents a milestone for Cephalon’s oncology program, firm says.
FDA Approves Cephalon’s Nuvigil With Bolded Warning For Rash
Company tells “The Pink Sheet” DAILY it is set to begin studies in other therapeutic areas to boost labeling before commercial launch.